Prolonged Treatment Interruption after Immunologic Response to Highly Active Antiretroviral Therapy

Clinical Infectious Diseases

Volumn 37, Issue 11, 2003, Pages 1541-1548

  Tarwater, Patrick M ^a   Parish, Michelle ^b   Gallant, Joel E ^a,b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPOATROPHY; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 0345119074     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/379514     Document Type: Article

References (13)

1. Walker B. Treatment interruption in primary HIV infection [abstract ThOrB259]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona, Spain). Barcelona: Prous Science, S.A., 2002:208.
2. Hirschel B, Fagaard C, Oxenius A, et al. SSITT: a prospective trial of treatment interruption in HIV infection [abstract 528]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:250.
3. Dybul M. Treatment interruption in chronic HIV infection [abstract ThOrB261]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona, Spain). Barcelona: Prous Science, S.A., 2002:208.
4. Ananworanich J, Cardiello P, Strasuebkul P, et al. HIV-NAT 001.4: a prospective randomized trial of structured treatment interruption in patients with chronic HIV infection [abstract 64]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:80.
5. Vella S, Giuliano M, Palmisano L, et al. ISS-PART: a prospective, randomized, multi-center clinical trial of intermittent therapy in HIV+ subjects with persistent suppression of viral replication [abstract 66]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:81.
6. Dybul M, Nies-Kraske E, Dauchner M, et al. A randomized controlled trial of long cycle structured intermittent versus continuous ARV therapy for chronic HIV infection [abstract 68lb]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:82.
7. Katlama C, Dominguez S, Duvivier C, et al. Long-term benefit of treatment interruption in salvage therapy (GIGHAART ANRS 097) [abstract 68]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:81.
8. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14:2857-67.
9. Lawrence J, Mayers D, Hullsiek KH, et al. Structured treatment interruption in patients with multi-drug resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-46.
10. Krolewiecki AJ, Bouzas MB, Cahn P, et al. Treatment discontinuation in patients who started antiretroviral therapy following the 1996 IAS-USA recommendations: a prospective randomized trial [abstract ThOrB1440]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona, Spain). Barcelona: Prous Science, S.A., 2002:203.
11. Molina M, Gil P, Granzio JJ, Górgolas M. Discontinuation of antiretroviral therapy in patients with low risk of progression to AIDS [abstract H-1082]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:262.
12. + T-cell counts and plasma HIV-1 RNA levels [abstract 65]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:80.
13. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44:1049-60 (erratum: Biometrics 1989; 45:347).